Howson Pharmaceuticals" Engrenet is about to be approved.

On July 24, Howson Pharmaceuticals submitted a four-class generic Engelnet listing application into the "in the approval" stage, is expected to be approved in the near future as the first domestic imitation.
Ngrenet, a sodium-glucose synergetic protein 2 (SGLT-2) inhibitor developed by Bollinger Ingham, was approved for listing in the European Union in May 2014 and approved by the FDA in August 2014 for use in type 2 diabetes.
And Engrenet is also the first sugar-lowering drug to be shown to have cardiovascular benefits, and the FDA approved in December 2016 that it added indications to reduce the risk of cardiovascular death in adults with type 2 diabetes with cardiovascular disease.
September 2017, Engler net was approved to enter China, the commodity is named O Tangjing.
2019, O'Donnell's global sales reached EUR 2,152 million.
worldwide are currently listed with eight SGLT-2 inhibitors, of which FDA approved Kagrenet (Johnson and Johnson), Dagre Net (AstraZeneca), Ngrenet (Briglinger Ingerheim/Lilly) and Aggrenet (Mercado).
the four SGLT-2 inhibitors have more than $5 billion in market size in 2019, with Engler net accounting for more than half of the market.
China has 3 SGLT-2 inhibitors of Kagre Net, Dagre Net and Ngre net have been approved for listing, and the Mersadon Aggre net listing application has entered the "in approval" stage and is expected to be approved in the near future.
, the three SGLT-2 inhibitors approved in China are now being negotiated to be included in the Health Insurance Category B list.
, The winning bid value of Engrenet is 9.75 yuan/10mg.
Source: PharmaGo.